TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05518578: Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy

Sponsor: Supernus Pharmaceuticals, Inc. · Phase: PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 60 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$1,707,200

Rescue Site Savings

+$1,125,200

Unlock Full NCT05518578 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05518578 Rescue Dossier →